MannKind Corporation Announces Participation at Upcoming Conferences

Rhea-AI Summary

MannKind Corporation (MNKD) announced its participation in upcoming conferences to showcase its inhaled therapeutic products. The company will be presenting at Leerink Partners Global Biopharma Conference 2024 and Oppenheimer 34th Annual Healthcare MedTech & Services Conference. Interested parties can access the live webcast and replay on the company's website.

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will be participating at upcoming conferences.

• Leerink Partners Global Biopharma Conference 2024 – Investor Meetings, Monday, March 11, 2024

• Oppenheimer 34th Annual Healthcare MedTech & Services Conference – Corporate Presentation, Wednesday, March 13, 2024 at 9:20 am (ET) and Investor Meetings

Interested parties can access a link to the live webcast of the presentation from the Events & Presentations section of the Company’s website at https://investors.mannkindcorp.com/events-and-presentations. The webcast replay may be accessed at the same location for 14 days following the live presentation.

About MannKind

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.

We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.

With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, Twitter or Instagram.

MannKind Contact:
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com

When is MannKind Corporation (MNKD) participating in the Leerink Partners Global Biopharma Conference 2024?

MannKind Corporation (MNKD) will be participating in the Leerink Partners Global Biopharma Conference 2024 on Monday, March 11, 2024.

What is the focus of MannKind Corporation (MNKD)'s products?

MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases.

Where can interested parties access the live webcast of MannKind Corporation (MNKD)'s presentation?

Interested parties can access the live webcast of MannKind Corporation (MNKD)'s presentation on the Events & Presentations section of the company's website at https://investors.mannkindcorp.com/events-and-presentations.

For how long can the webcast replay of MannKind Corporation (MNKD)'s presentation be accessed?

The webcast replay of MannKind Corporation (MNKD)'s presentation can be accessed at the same location for 14 days following the live presentation.